Neil Sands
The Court of Appeal has backed the High Court’s approach to dealing with a ban on puberty blockers, dismissing an appeal from a transgender lobby group that argues it does not go far enough.
The appeal court cut short its summer break last week to hear the case, which was launched by the Professional Association for Transgender Health Aotearoa (PATHA) over the ban on new puberty blocker prescriptions for children with gender dysphoria.
The ban was announced in November, but the High Court ordered a month later that no steps should be taken to enforce it pending a judicial review scheduled for May.
PATHA then went to the Court of Appeal, arguing that the High Court order was ineffective because the regulations preventing new prescriptions for puberty blocker medicines technically remain in place, even if it is not being enforced pending the judicial review.
It said this meant that doctors who prescribe the medicines could face disciplinary action or even private prosecution for allegedly breaching their ethical responsibilities, saying anti-trans activists had threatened to launch such action.
Instead, PATHA said the court should direct the Health Minister Simeon Brown to advise Governor-General Dame Cindy Kiro to delay implementation of the regulations, or squash them entirely, a move the High Court said would be an “extraordinary” judicial intervention in the legislative process.
“Such an order would potentially pit the court against the executive council and that is constitutionally inappropriate,” Justice Michele Wilkinson-Smith said in her December judgement.
‘Negligible’ prosecution risk for doctors
A three-person Court of Appeal panel chaired by Justice Christine French effectively sidestepped the tricky constitutional debate by finding that Wilkinson-Smith’s interim measure was an effective remedy until the judicial review took place.
The panel questioned whether any medical disciplinary body would facilitate a complaint against a doctor when a High Court order was in place not to enforce the regulation.
“We agree with the Crown that, in light of the High Court’s order preventing enforcement of the regulations, it would be extraordinary for any of these public bodies to facilitate a complaint about the prescription of puberty blockers as unethical because it is illegal, when doing so would disregard the intent of an order of the High Court which has suspended the enforcement of the regulations,” it said.
It added: “Taking such steps would be an unduly narrow and technical interpretation of the rule of law.”
In addition, it said the risk a private prosecution was negligible as it would have to be approved by a court registrar or district court judge, who would act consistently with the High Court’s order.
“In light of this court making that clear in this judgment, the relief granted by the High Court is effective to preserve PATHA’s position. Accordingly, the appeal is dismissed,” it said.
On the issue of costs, the court noted that PATHA’s appeal was unsuccessful.
“However, it has gained further clarity and assurance from this court as to the implications of the High Court’s order, which it would not have gained otherwise. We accept it was in the public interest for the issue to be pursued. Costs will lie where they fall.”
PATHA told the court last week that the first medical community heard about the ban was via a November 19 media release on the NZ First website issued by Associate Health Minister Casey Costello.
Costello’s statement characterised the decision as a victory in the “war on woke”, saying: “Puberty blockers cause irreversible harm to bone density, fertility, brain development and future sexual function.”
PATHA’s counsel Victoria Casey KC said there had been no consultation involving medical experts and questioned the evidence cited by Costello.
“It was New Zealand First who pushed it. They got it over the line, and they did so for these reasons, which are completely unacceptable reasons and completely misinformed on the facts.” she said.
The Court of Appeal panel said its judgment should not be interpreted as a comment on the judicial review in May, which is scheduled for a two-day hearing.

0 Comments